{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T15:03:08Z","timestamp":1794927788799,"version":"4.9.1"},"reference-count":10,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T00:00:00Z","timestamp":1786320000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","diabetesresearchclinicalpractice.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diabetes Research and Clinical Practice"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.diabres.2026.113490","type":"journal-article","created":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T23:17:49Z","timestamp":1786576669000},"page":"113490","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Duration and characteristics of hypoglycemia with once-weekly insulin efsitora alfa versus once-daily basal insulins in adults with type 2 diabetes: Exploratory safety analysis of QWINT 2-4"],"prefix":"10.1016","volume":"239","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-4439-7374","authenticated-orcid":false,"given":"Natalie","family":"Bellini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9050-5584","authenticated-orcid":false,"given":"Richard M.","family":"Bergenstal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2976-1690","authenticated-orcid":false,"given":"Marga","family":"Gim\u00e9nez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr","given":"Eugene E.","family":"Wright","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Case","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Molly C.","family":"Carr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ada Leticia","family":"Murro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karli","family":"Gunn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.diabres.2026.113490_b0005","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1056\/NEJMoa2502796","article-title":"Weekly fixed-dose insulin Efsitora in type 2 diabetes without previous insulin therapy","volume":"393","author":"Rosenstock","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diabres.2026.113490_b0010","doi-asserted-by":"crossref","first-page":"2290","DOI":"10.1016\/S0140-6736(25)01069-4","article-title":"Once-weekly insulin efsitora alfa versus once-daily insulin glargine U100 in adults with type 2 diabetes treated with basal and prandial insulin (QWINT-4): a phase 3, randomised, non-inferiority trial","volume":"405","author":"Blevins","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.diabres.2026.113490_b0015","doi-asserted-by":"crossref","first-page":"2279","DOI":"10.1016\/S0140-6736(25)01044-X","article-title":"Once-weekly insulin efsitora alfa versus once-daily insulin degludec in adults with type 2 diabetes currently treated with basal insulin (QWINT-3): a phase 3, randomised, non-inferiority trial","volume":"405","author":"Philis-Tsimikas","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.diabres.2026.113490_b0020","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.1056\/NEJMoa2403953","article-title":"Insulin efsitora versus degludec in type 2 diabetes without previous insulin treatment","volume":"391","author":"Wysham","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diabres.2026.113490_b0025","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.2337\/dci19-0028","article-title":"Clinical targets for continuous glucose monitoring data interpretation: recommendations from the international consensus on time in range","volume":"42","author":"Battelino","year":"2019","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabres.2026.113490_b0030","doi-asserted-by":"crossref","first-page":"2482","DOI":"10.1111\/dom.70419","article-title":"CGM-derived efficacy and overall safety of once-weekly insulin efsitora alfa (efsitora) relative to day of administration in adults with type 2 diabetes","volume":"28","author":"Martens","year":"2026","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.diabres.2026.113490_b0035","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1007\/s13300-024-01605-7","article-title":"Frequency and severity of hypoglycemia under conditions of increased hypoglycemic risk with insulin efsitora alfa versus insulin glargine treatment in participants with type 2 diabetes","volume":"15","author":"Heise","year":"2024","journal-title":"Diabetes Therapy"},{"key":"10.1016\/j.diabres.2026.113490_b0040","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.2337\/dc17-1600","article-title":"International consensus on use of continuous glucose monitoring","volume":"40","author":"Danne","year":"2017","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabres.2026.113490_b0045","doi-asserted-by":"crossref","first-page":"729","DOI":"10.2337\/dc23-2136","article-title":"Continuous glucose monitoring\u2013based metrics and hypoglycemia duration in insulin-experienced individuals with long-standing type 2 diabetes switched from a daily basal insulin to once-weekly insulin icodec: post hoc analysis of ONWARDS 2 and ONWARDS 4","volume":"47","author":"Bajaj","year":"2024","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabres.2026.113490_b0050","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/S2213-8587(24)00220-1","article-title":"Continuous glucose monitoring-based metrics and the duration of hypoglycaemia events with once-weekly insulin icodec versus once-daily insulin glargine U100 in insulin-naive type 2 diabetes: an exploratory analysis of ONWARDS 1","volume":"12","author":"Bergenstal","year":"2024","journal-title":"Lancet Diabet Endocrinol"}],"container-title":["Diabetes Research and Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168822726004109?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168822726004109?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T01:16:02Z","timestamp":1792804562000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168822726004109"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":10,"alternative-id":["S0168822726004109"],"URL":"https:\/\/doi.org\/10.1016\/j.diabres.2026.113490","relation":{},"ISSN":["0168-8227"],"issn-type":[{"value":"0168-8227","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Duration and characteristics of hypoglycemia with once-weekly insulin efsitora alfa versus once-daily basal insulins in adults with type 2 diabetes: Exploratory safety analysis of QWINT 2-4","name":"articletitle","label":"Article Title"},{"value":"Diabetes Research and Clinical Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.diabres.2026.113490","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Eli Lilly and Company. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"113490"}}